v3.26.1
Fair Value Measurements
 6 Months Ended
Jun. 30, 2026
Fair Value Disclosures [Abstract]  
Fair Value Measurements FAIR VALUE MEASUREMENTS
Our policies for managing risk related to foreign currency, interest
rates, credit and markets and our process for determining fair
value have not changed from those described in our Annual
Report on Form 10-K for 2025.
In the six months 2026 we recorded $271 of contingent
consideration related to the acquisition of Amplitude Vascular
Systems, Inc. (AVS) described in Note 7.
In 2025 we assumed contingent consideration liabilities with a fair
value of $90 related to previous acquisitions made by Inari
Medical, Inc. (Inari). Refer to Note 7 for further information on the
acquisition of Inari.
There were no significant transfers into or out of any level of the
fair value hierarchy in 2026.
Assets Measured at Fair Value
June 30
December 31
2026
2025
Cash and cash equivalents
$3,391
$4,011
Trading marketable securities
336
307
Level 1 - Assets
$3,727
$4,318
Available-for-sale marketable securities:
Corporate and asset-backed debt securities
$47
$52
United States treasury debt securities
38
37
Total available-for-sale marketable securities
$85
$89
Foreign currency exchange forward contracts
81
46
Level 2 - Assets
$166
$135
Total assets measured at fair value
$3,893
$4,453
Liabilities Measured at Fair Value
June 30
December 31
2026
2025
Deferred compensation arrangements
$336
$307
Level 1 - Liabilities
$336
$307
Foreign currency exchange forward contracts
$107
$170
Level 2 - Liabilities
$107
$170
Contingent consideration:
Beginning
$518
$452
Additions
271
123
Change in estimate and foreign exchange
7
24
Settlements
(40)
(81)
Ending
$756
$518
Level 3 - Liabilities
$756
$518
Total liabilities measured at fair value
$1,199
$995
Fair Value of Available for Sale Securities by Maturity
June 30
December 31
2026
2025
Due in one year or less
$31
$41
Due after one year through three years
$54
$48
On June 30, 2026 and December 31, 2025 the aggregate
difference between the cost and fair value of available-for-sale
marketable securities was nominal. Interest income on cash and
cash equivalents, short-term investments and income from
marketable securities was $26 and $24 in the three months 2026
and 2025, and $60 and $62 in the six months 2026 and 2025,
which was recorded in other income.
Our investments in available-for-sale marketable securities had a
minimum credit quality rating of A2 (Moody's), A (Standard &
Poor's) and A (Fitch). We do not plan to sell the investments, and
it is not more likely than not that we will be required to sell the
investments before recovery of their amortized cost basis, which
may be maturity.